BACKGROUND: Cell therapy is becoming a promising strategy to cure myocardial infarction. There were many cell sources be a candidate for cell therapy. In this study, we evaluated the effect of human cord blood MSC (CBMSC), human amniotic membrane derived epithelial stem cell (AMESC) and human adipose tissue derived MSC (ATMSC) on repair of damaged heart tissue. METHODS: Myocardial infarction was induced by cryoinjury method. At ten days after myocardial infarction, human CBMSC, AMESC and ATMSC were administrated to nude rat. Four weeks after implantation, defect size was evaluated with micro PET and echocardiography was performed to evaluate cardiac function. RESULTS: Defect size by micro PET was decreased 50%, 40% and 39% in CBMSC, AMESC and ATMSC group compared to control group respectively. LV ejection fraction increased 25%, 21% and 31% in CBMSC, AMESC and ATMSC group compared to control group respectively. CONCLUSIONS: human CBMSC, AMESC and ATMSC administration effectively decreased infarct size in MI model.